NCT04483583View on ClinicalTrials.gov

Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After PCI

PHASE4CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

December 8, 2020

Primary Completion Date

January 7, 2025

Study Completion Date

January 7, 2025

Conditions
Coronary Artery Disease
Interventions
DRUG

Ticagrelor 60mg

Patients will be administered a 180 mg loading dose followed by a 60 mg bid for the duration of the study.

DRUG

Clopidogrel

Patients will be administered a 600 mg loading dose followed by a 75 mg daily for the duration of the study.

Trial Locations (1)

32209

University of Florida, Jacksonville

All Listed Sponsors
lead

University of Florida

OTHER

NCT04483583 - Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After PCI | Biotech Hunter | Biotech Hunter